Eli Lilly's Trulicity approved in the EU for type 2 diabetes

26 November 2014

US drug major Eli Lilly (NYSE: LLY) has received approval from the European Commission for its GLP-1 receptor agonist Trulicity (dulaglutide) for the improvement of glycemic control in adult type 2 diabetes.

The once-weekly therapy will be available to European patients from 2015. It is indicated in combination with other glucose-lowering medicines including insulin, when these together with diet and exercise do not adequately provide glycemic control. It is also indicated as a monotherapy when diet and exercise alone do not provide adequate glycemic control in patients for whom the use of metformin is inappropriate due to intolerance or contraindications.

Trulicity’s recommended dose is 1.5mg as a combination therapy, and 0.75mg as a monotherapy. The drug was recently approved by the US Food and Drug Administration (The Pharma Letter September 19).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK